Zelluna’s pipeline assets target a blend of antigens that are either clinically or preclinically validated and expressed across a broad range of solid tumour indications, providing high potential for patient impact and a huge market opportunity.
- MAGE-A4 and PRAME are clinically validated TCR targets in solid cancers: a MAGE-A4-targeting TCR therapy has received market approval, and a PRAME-targeting TCR therapy is in a Phase 3 registration trial.
- KKLC-1 is a preclinically validated solid cancer target.
Zelluna’s positive regulatory interactions and plug-in manufacturing process apply across the entire pipeline, helping to de-risk the development path for all programmes.
